title: [A meta-analysis of the efficacy and safety of the anti-obesity agent Rimonabant].
abstract: A meta-analysis of all randomised controlled trials examining the efficacy and safety of the anti-obesity agent Rimonabant (Acomplia, 20 mg/d) found an efficacy of 4.7 kg (4.1-5.3) more weight loss after one year compared to placebo. Rimonabant increased the risk of adverse events, including depressive episodes and anxiety, despite depressive symptoms being an exclusion criterion in these trials. This, combined with an increased risk of suicidality during Rimonabant treatment, warrants increased awareness from prescribing physicians.
authors.affiliation: Frederiksberg Hospital, Parker Instituttet, Københavns Universitet, Det Biovidenskabelige Fakultet, Institut for Human Ernaering, Frederiksberg C.
authors.forename: Robin
authors.initials: R
authors.lastname: Christensen
authors.forename: Pernelle Kruse
authors.initials: PK
authors.lastname: Kristensen
authors.forename: Else Marie
authors.initials: EM
authors.lastname: Bartels
authors.forename: Henning
authors.initials: H
authors.lastname: Bliddal
authors.forename: Arne V
authors.initials: AV
authors.lastname: Astrup